Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Roshan Mathew

Interventional Cardiology Owensboro, KY Medical Doctor

NPI 1093820953 CMS profile 736365

3110 Fairview Dr, Owensboro, KY 42303

Open in the dashboard

General payments

$7,308

484 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Roshan Mathew of Owensboro, KY is reported in the CMS Open Payments database as having received $7,308 across 484 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 49th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $665 32
2024 General $800 32
2023 General $509 31
2022 General $1,345 80
2021 General $1,051 80
2020 General $1,210 80
2019 General $1,726 149

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roshan Mathew
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Roshan Mathew were reported at $665. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Roshan Mathew Interventional Cardiology median Middle half National median
2019 $1,726 $1,097 $329–$3,048 $163
2020 $1,210 $473 $161–$1,480 $114
2021 $1,051 $677 $233–$1,827 $132
2022 $1,345 $978 $333–$2,724 $149
2023 $509 $1,136 $382–$2,986 $160
2024 $800 $1,181 $395–$3,326 $164
2025 $665 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $1,140 84 payments
  2. Amgen Inc. $807 51 payments
  3. Novartis Pharmaceuticals Corporation $756 53 payments
  4. Pfizer Inc. $478 42 payments
  5. Actelion Pharmaceuticals US, Inc. $462 19 payments
  6. Amarin Pharma Inc. $370 47 payments
  7. E.R. Squibb & Sons, L.L.C. $327 22 payments
  8. Sanofi-Aventis U.S. LLC $299 18 payments
  9. Merck Sharp & Dohme Corporation $244 15 payments
  10. Terumo Medical Corporation $216 3 payments
  11. Other $2,210 130 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,952 443 payments
  2. Education $356 41 payments
Products named General payments · program years 2019–2025
  1. XARELTO $1,099 81 payments
  2. Repatha $791 50 payments
  3. ENTRESTO $642 45 payments
  4. ELIQUIS $437 39 payments
  5. OPSUMIT $380 15 payments
  6. UPTRAVI $350 12 payments
  7. VERQUVO $327 20 payments
  8. Corlanor $290 19 payments
  9. Vascepa Cardiovascular $185 17 payments
  10. Vascepa Hypertriglyceridemia $185 30 payments
  11. Other $3,741 222 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 93 drugs

Part D claims

23,427

Median for Interventional Cardiology: 2,236

Drug cost

$4,062,345

Median for Interventional Cardiology: $380,412

Branded share of claims

38.9%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 1,975 $2,090,657
Xarelto Rivaroxaban Brand 486 $533,526
Entresto Sacubitril/Valsartan Brand 471 $530,228
Brilinta Ticagrelor Brand 184 $173,593
Repatha Sureclick Evolocumab Brand 179 $169,931
Farxiga Dapagliflozin Propanediol Brand 142 $116,052
Jardiance Empagliflozin Brand 64 $81,450
Multaq Dronedarone Hcl Brand 43 $61,803
Metoprolol Succinate Generic 2,077 $22,730
Clopidogrel Clopidogrel Bisulfate Brand 2,364 $21,582

The 10 drugs with the highest cost, of 93 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 93 billing codes

Paid by Medicare

$848,203

Of which drugs: $10,005

Medicare patients

2,494

Average age 76

Services billed

18,072

1,206 women, 1,288 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 48%
Arthritis 48%
Diabetes 37%
Atrial fibrillation 33%
Chronic kidney disease 29%
Heart failure 25%
COPD 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 390 1,557 $9,997

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $87
$87 486 —
VERQUVO
  • Merck Sharp & Dohme Corporation $84
$84 21 —
MULTAQ
  • SANOFI-AVENTIS U.S. LLC $38
$38 43 —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $34
$34 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $29
$29 64 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

484 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record